vs
HORACE MANN EDUCATORS CORP（HMN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是HORACE MANN EDUCATORS CORP的1.8倍（$772.1M vs $434.8M），HORACE MANN EDUCATORS CORP同比增速更快（6.3% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 6.1%）
贺拉斯曼是一家总部位于美国伊利诺伊州的金融服务企业，主营汽车保险、财产保险、补充保险与人寿保险业务，同时提供退休年金、共同基金等金融产品，核心服务群体为教育工作者及其家庭。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HMN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$434.8M
营收增速更快
HMN
高出0.5%
5.9%
两年增速更快
RVTY
近两年复合增速
6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $434.8M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.5% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | 6.3% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.87 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HMNRVTY
| Q4 25 | $434.8M | $772.1M | ||
| Q3 25 | $438.5M | $698.9M | ||
| Q2 25 | $411.7M | $720.3M | ||
| Q1 25 | $416.4M | $664.8M | ||
| Q4 24 | $409.0M | $729.4M | ||
| Q3 24 | $412.1M | $684.0M | ||
| Q2 24 | $388.1M | $691.7M | ||
| Q1 24 | $386.0M | $649.9M |
净利润HMNRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $58.3M | $46.7M | ||
| Q2 25 | $29.4M | $53.9M | ||
| Q1 25 | $38.2M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $34.3M | $94.4M | ||
| Q2 24 | $3.8M | $55.4M | ||
| Q1 24 | $26.5M | $26.0M |
毛利率HMNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HMNRVTY
| Q4 25 | 10.5% | 14.5% | ||
| Q3 25 | 16.3% | 11.7% | ||
| Q2 25 | 8.9% | 12.6% | ||
| Q1 25 | 11.4% | 10.9% | ||
| Q4 24 | 11.8% | 16.3% | ||
| Q3 24 | 10.4% | 14.3% | ||
| Q2 24 | 1.2% | 12.4% | ||
| Q1 24 | 8.5% | 6.8% |
净利率HMNRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 13.3% | 6.7% | ||
| Q2 25 | 7.1% | 7.5% | ||
| Q1 25 | 9.2% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 8.3% | 13.8% | ||
| Q2 24 | 1.0% | 8.0% | ||
| Q1 24 | 6.9% | 4.0% |
每股收益（稀释后）HMNRVTY
| Q4 25 | $0.87 | $0.86 | ||
| Q3 25 | $1.40 | $0.40 | ||
| Q2 25 | $0.71 | $0.46 | ||
| Q1 25 | $0.92 | $0.35 | ||
| Q4 24 | $0.92 | $0.77 | ||
| Q3 24 | $0.83 | $0.77 | ||
| Q2 24 | $0.09 | $0.45 | ||
| Q1 24 | $0.64 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.5M | $919.9M |
| 总债务越低越好 | $593.4M | — |
| 股东权益账面价值 | $1.5B | $7.3B |
| 总资产 | $15.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.40× | — |
8季度趋势，按日历期对齐
现金及短期投资HMNRVTY
| Q4 25 | $27.5M | $919.9M | ||
| Q3 25 | $46.7M | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $38.1M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务HMNRVTY
| Q4 25 | $593.4M | — | ||
| Q3 25 | $842.9M | — | ||
| Q2 25 | $547.5M | — | ||
| Q1 25 | $547.2M | — | ||
| Q4 24 | $547.0M | — | ||
| Q3 24 | $546.7M | — | ||
| Q2 24 | $546.5M | — | ||
| Q1 24 | $546.2M | — |
股东权益HMNRVTY
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产HMNRVTY
| Q4 25 | $15.3B | $12.2B | ||
| Q3 25 | $15.5B | $12.1B | ||
| Q2 25 | $14.7B | $12.4B | ||
| Q1 25 | $14.4B | $12.4B | ||
| Q4 24 | $14.5B | $12.4B | ||
| Q3 24 | $14.7B | $12.8B | ||
| Q2 24 | $14.3B | $13.4B | ||
| Q1 24 | $14.2B | $13.4B |
负债/权益比HMNRVTY
| Q4 25 | 0.40× | — | ||
| Q3 25 | 0.58× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.42× | — | ||
| Q3 24 | 0.42× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $553.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流HMNRVTY
| Q4 25 | $553.2M | $182.0M | ||
| Q3 25 | $151.2M | $138.5M | ||
| Q2 25 | $131.3M | $134.3M | ||
| Q1 25 | $140.8M | $128.2M | ||
| Q4 24 | $452.1M | $174.2M | ||
| Q3 24 | $143.9M | $147.9M | ||
| Q2 24 | $40.2M | $158.6M | ||
| Q1 24 | $74.5M | $147.6M |
自由现金流HMNRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率HMNRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度HMNRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率HMNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.59× | 2.97× | ||
| Q2 25 | 4.47× | 2.49× | ||
| Q1 25 | 3.69× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 4.20× | 1.57× | ||
| Q2 24 | 10.58× | 2.87× | ||
| Q1 24 | 2.81× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HMN
| Property And Casualty | $224.3M | 52% |
| Life And Retirement | $139.6M | 32% |
| Supplemental And Group Benefits | $77.0M | 18% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
